N/A
Manufactured by Waylis Therapeutics LLC
5,587 FDA adverse event reports analyzed
Last updated: 2026-04-15
CARVEDILOL PHOSPHATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Waylis Therapeutics LLC. The most commonly reported adverse reactions for CARVEDILOL PHOSPHATE include DIZZINESS, FATIGUE, DRUG INEFFECTIVE, DYSPNOEA, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARVEDILOL PHOSPHATE.
Out of 2,953 classified reports for CARVEDILOL PHOSPHATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 5,587 FDA FAERS reports that mention CARVEDILOL PHOSPHATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DIZZINESS, FATIGUE, DRUG INEFFECTIVE, DYSPNOEA, NAUSEA, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Waylis Therapeutics LLC in connection with CARVEDILOL PHOSPHATE. Always verify the specific product and NDC with your pharmacist.